June 1, 2021 - Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors

SAN DIEGO – June 1, 2021 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the appointment of Georgia Erbez and Elizabeth (Liz) Cermak to its Board of Directors. Ms. Erbez and Ms. Cermak are accomplished, experienced…

May 24, 2021 - On Target Laboratories, Inc. Announces Results of Phase 3 Trial for Pafolacianine Sodium Injection for Intraoperative Illumination of Folate Receptor Positive Ovarian Cancer

WEST LAFAYETTE, IN – May 20, 2021 - On Target Laboratories, Inc., a privately held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced results of the 006 Study, a Phase 3, randomized, multi-center, prospective, open-label…

April 27, 2021 - Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming a Publicly Listed Company to Address Unmet Needs of Men and Women Through Development of Androgen and Metabolic Therapies

Existing Clarus investors, led by H.I.G. Capital, will invest an additional $25 million in support of the company

NORTHBROOK, IL AND GREENWICH, CT – April 27, 2021 - Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and Blue Water Acquisition Corp. (NASDAQ: BLUW)…

March 30, 2021 - Augmedics, Augmented Reality Surgical Image Guidance Pioneer, Raises $36 Million in Series C Fundraising

CHICAGO – March 30, 2021 – Augmedics, a pioneer in augmented reality surgical image guidance, announced today that it has raised $36 million in an over-subscribed Series C financing with an international syndicate of Israel-US investors. This comes only eight months after the company…

March 11, 2021 - PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

MALVERN, PA & SAN DIEGO – March 11, 2021 – PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract…

January 21, 2021 - ONTOZRY™ (cenobamate) Receives Positive CHMP Opinion for the Adjunctive Treatment of Uncontrolled Focal Onset Seizures in Adults*

ZUG, SWITZERLAND – January 21, 2021 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use…

January 12, 2021 - CardioFocus Invited to Participate in 23^rd Annual ICR Conference and Needham Virtual Growth Conference

MARLBOROUGH, MA – January 12, 2021 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference,…

January 11, 2021 - CardioFocus® Annouces Expanded Distribution Partnership with Microport™ CRM to Include Spain and Portugal

MARLBOROUGH, MA – January 11, 2021 – CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to…

January 4, 2021 - Angelini Pharma Acquires Arvelle Therapeutics to Create a Leading European Innovator in Central Nervous System (CNS) and Mental Health Disorder Treatments

ROME – January 4, 2021 – Angelini Pharma, an international pharmaceutical company which is a part of the private ItalianAngelini Group – and Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovativetreatments…

December 21, 2020 - Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study

SAN DIEGO – December 21, 2020 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that the first patient has been enrolled in the Phase 3, RESUME-1, clinical study of tolperisone, a novel, non-opioid, centrally…

December 8, 2020 - Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study

SAN DIEGO – December 8, 2020 – Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscularconditions, today announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. Thestudy, utilizing a validated…

November 24, 2020 - Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research

SAN DIEGO – November 23, 2020 - Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of results from the dose-ranging Phase 2 STAR Study of tolperisone in patients with acute and painful muscle spasms…

October 22, 2020 - Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials

BRIDGEWATER, NJ - October 22, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-…

July 8, 2020 - H.I.G. Capital Acquires Project Informatica

MILAN – July 8, 2020 – H.I.G. Europe (“H.I.G.”), the European affiliate of H.I.G. Capital, a leading global private equity investment firm with more than €34 billion of equity capital under management, announced today the acquisition by an affiliate of a controlling stake…